Search

The article reports on the discontinuation of the Phase III lung cancer trial A4021016 by Pfizer Inc. in the U.S. It states that the trial aims to examine the effects of figitumumab as first line treatment to patients with advanced nonadenocarcinoma non-small cell lung cancer (NSCLC). The study conducted by the independent data safety monitoring committee (DSMC) shows that the addition of figitumumab to paclitaxel is unlikely to meet the primary endpoint of improving overall survival.

The article focuses on a study aimed at determining the effectiveness of protein supplement IMN 1207 in preventing weight loss in lung cancer patients. It reports that the study is being conducted by Immunotec SA at the Beaumont Hospital in Royal Oak, Michigan, and gives details of IMN's formulation including a whey protein isolate called Immunocal. Also discussed is the involvement of hospital's community clinical oncology program (CCOP) in the study.

The article presents results of the Phase III cancer study by the Genentech Inc. and OSI Pharmaceuticals Inc. Genentech and OSI have revealed that a global Phase III study has met its primary endpoint and demonstrated that Tarceva significantly extended the time patients with advanced non-small cell lung cancer. The primary endpoint of the companies' study was progression-free survival and secondary endpoints include safety and overall survival.